{
    "organizations": [],
    "uuid": "c93c4a176c7ae6b45c81dfe5e8ba556cfbd4af98",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/30/globe-newswire-arbutus-announces-conference-call-to-provide-a-corporate-update-and-first-quarter-2018-financial-results.html",
    "ord_in_thread": 0,
    "title": "Arbutus Announces Conference Call to Provide a Corporate Update and First Quarter 2018 Financial Results",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "VANCOUVER, British Columbia and WARMINSTER, Pa., April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss first quarter 2018 financial results and provide a corporate update.\nTo access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com . Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.\nAn archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 4169558.\nAbout Arbutus\nArbutus Biopharma Corporation is a publicly traded (Nasdaq:ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care (SOC) and contribute to a curative combination regimen to improve patient outcomes and deliver a potential cure for HBV. For more information, visit www.arbutusbio.com .\nContact Information\nInvestors\nTiffany Tolmie\nManager, Investor Relations\nPhone: 604-419-3200\nEmail: ttolmie@arbutusbio.com\nMedia\nDavid Schull\nRusso Partners\nPhone: 858-717-2310\nEmail: david.schull@russopartnersllc.com\nSource:Arbutus Biopharma Corporation",
    "published": "2018-04-30T17:00:00.000+03:00",
    "crawled": "2018-04-30T17:29:10.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "vancouver",
        "british",
        "columbia",
        "warminster",
        "april",
        "globe",
        "newswire",
        "arbutus",
        "biopharma",
        "corporation",
        "nasdaq",
        "abus",
        "hepatitis",
        "b",
        "virus",
        "hbv",
        "therapeutic",
        "solution",
        "company",
        "today",
        "announced",
        "hold",
        "conference",
        "call",
        "thursday",
        "may",
        "pm",
        "pacific",
        "time",
        "pm",
        "eastern",
        "time",
        "discus",
        "first",
        "quarter",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "access",
        "conference",
        "call",
        "live",
        "webcast",
        "call",
        "accessed",
        "investor",
        "section",
        "arbutus",
        "website",
        "alternatively",
        "access",
        "conference",
        "call",
        "please",
        "dial",
        "archived",
        "webcast",
        "available",
        "arbutus",
        "website",
        "event",
        "alternatively",
        "may",
        "access",
        "replay",
        "conference",
        "call",
        "calling",
        "referencing",
        "conference",
        "id",
        "arbutus",
        "arbutus",
        "biopharma",
        "corporation",
        "publicly",
        "traded",
        "nasdaq",
        "abus",
        "biopharmaceutical",
        "company",
        "dedicated",
        "discovering",
        "developing",
        "commercializing",
        "cure",
        "patient",
        "suffering",
        "chronic",
        "hepatitis",
        "b",
        "hbv",
        "infection",
        "arbutus",
        "developing",
        "multiple",
        "drug",
        "candidate",
        "potential",
        "improve",
        "upon",
        "standard",
        "care",
        "soc",
        "contribute",
        "curative",
        "combination",
        "regimen",
        "improve",
        "patient",
        "outcome",
        "deliver",
        "potential",
        "cure",
        "hbv",
        "information",
        "visit",
        "contact",
        "information",
        "investor",
        "tiffany",
        "tolmie",
        "manager",
        "investor",
        "relation",
        "phone",
        "email",
        "ttolmie",
        "medium",
        "david",
        "schull",
        "russo",
        "partner",
        "phone",
        "email",
        "source",
        "arbutus",
        "biopharma",
        "corporation"
    ]
}